Radiolabeled Divalent Peptidomimetic Vitronectin Receptor Antagonists as Potential Tumor Radiotherapeutic and Imaging Agents

• Published in: Bioconjugate chemistry 2007-07, Vol.18 (4), p.1266-1279
• Main Authors: Harris, Thomas D, Cheesman, Edward, Harris, Anthony R, Sachleben, Richard, Edwards, D. Scott, Liu, Shuang, Bartis, Judit, Ellars, Charles, Onthank, Dave, Yalamanchili, Padmaja, Heminway, Stuart, Silva, Paula, Robinson, Simon, Lazewatsky, Joel, Rajopadhye, Milind, Barrett, John
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - diagnostic imaging; Adenocarcinoma - metabolism; Adenocarcinoma - radiotherapy; Animals; Binding, Competitive; Breast Neoplasms - diagnostic imaging; Breast Neoplasms - metabolism; Breast Neoplasms - radiotherapy; Cell growth; Diagnostic Imaging; Drug therapy; Female; Heterocyclic Compounds, 1-Ring - chemistry; Heterocyclic Compounds, 1-Ring - pharmacokinetics; Heterocyclic Compounds, 1-Ring - therapeutic use; Indium Radioisotopes - chemistry; Indium Radioisotopes - pharmacokinetics; Indium Radioisotopes - therapeutic use; Integrin alphaVbeta3 - antagonists & inhibitors; Integrin alphaVbeta3 - metabolism; Lutetium - chemistry; Lutetium - pharmacokinetics; Lutetium - therapeutic use; Mice; Peptides; Peptides - chemistry; Peptides - pharmacokinetics; Peptides - therapeutic use; Radiation therapy; Radioisotopes - chemistry; Radioisotopes - pharmacokinetics; Radioisotopes - therapeutic use; Radionuclide Imaging; Radiopharmaceuticals - chemistry; Radiopharmaceuticals - pharmacokinetics; Radiopharmaceuticals - therapeutic use; Rodents; Sulfonamides - chemistry; Sulfonamides - pharmacokinetics; Sulfonamides - therapeutic use; T cell receptors; Tissue Distribution; Tumors
• ISSN: 1043-1802; 1520-4812
• DOI: 10.1021/bc070002+

The integrin receptor αvβ3 is overexpressed on the endothelial cells of growing tumors and on some tumor cells themselves. A radiolabeled αvβ3 antagonists belonging to the quinolin-4-one class of peptidomimetics (TA138) was previously shown to exhibit high affinity for integrin αvβ3 and high selectivity versus other integrin receptors. 111In-TA138 exhibited high tumor uptake in the c-neu Oncomouse mammary adenocarcinoma model and produced excellent scintigraphic images. This study describes the synthesis of eight divalent versions of TA138 and their evaluation as potential tumor radiotherapeutic agents. The two main variables in this study were the length of the spacer bridging the biotargeting moieties and the total negative charge of the molecules imparted by the cysteic acid pharmacokinetic modifiers. Receptor affinity was evaluated in a panel of integrin receptor affinity assays, and biodistribution studies using the 111In-labeled derivatives were carried out in the c-neu Oncomouse model. All divalent agents maintained the high receptor affinity and selectivity of TA138, and six of the eight 111In derivatives exhibited blood clearance that was faster than 111In-TA138 at 24 h postinjection (PI). All divalent agents exhibited tumor uptake and retention at 24 h PI that was higher than 111In-TA138. Tumor/organ ratios were improved for most of the divalent agents at 24 h PI in critical nontarget organs marrow, kidney, and liver, with the agents having intermediate-length spacers (29−43 Å) showing the largest improvement. As an example, 111In-15 showed tumor uptake of 14.3% ID/g at 24 h PI and tumor/organ ratios as follows:  marrow, 3.24; kidney, 7.29; liver, 8.51. A comparison of therapeutic indices for 90Y-TA138 and 177Lu-15 indicate an improved therapeutic index for the divalent agent. The implications for radiotherapeutic applications and the mechanism of this multivalent effect are discussed.